• LAST PRICE
    4.9200
  • TODAY'S CHANGE (%)
    Trending Up0.1100 (2.2869%)
  • Bid / Lots
    4.8000/ 1
  • Ask / Lots
    5.0000/ 2
  • Open / Previous Close
    4.7900 / 4.8100
  • Day Range
    Low 4.7500
    High 4.9250
  • 52 Week Range
    Low 1.5900
    High 7.7700
  • Volume
    268,106
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 4.81
TimeVolumeKOD
09:32 ET9724.79
09:42 ET20004.8
09:44 ET34734.8
09:46 ET9914.785
09:48 ET2004.79
09:50 ET13504.85
09:51 ET2524.84
09:53 ET1004.84
10:04 ET1004.84
10:06 ET9874.85
10:08 ET3004.85
10:09 ET2004.825
10:13 ET7004.85
10:15 ET3684.87
10:18 ET10004.835
10:20 ET15714.85
10:22 ET1784.8268
10:24 ET5004.835
10:26 ET1004.835
10:27 ET12004.85
10:29 ET13004.835
10:31 ET4024.835
10:33 ET6974.86
10:36 ET4294.871
10:38 ET7004.86
10:40 ET7004.84
10:42 ET9164.83
10:44 ET4364.83
10:45 ET5004.845
10:47 ET1344.845
10:49 ET2014.8301
10:51 ET43254.83
10:54 ET31964.85
10:58 ET10004.85
11:02 ET7004.845
11:03 ET7004.845
11:05 ET4004.845
11:07 ET12004.8451
11:09 ET6004.84
11:12 ET27104.835
11:16 ET3004.84
11:18 ET2004.84
11:20 ET1004.845
11:21 ET5004.845
11:23 ET75564.815
11:25 ET15004.8451
11:27 ET4004.85
11:34 ET18504.85
11:36 ET1004.83
11:39 ET7464.84
11:41 ET1004.84
11:43 ET15754.85
11:48 ET10304.85
11:52 ET3264.85
11:56 ET2254.85
11:59 ET2004.85
12:06 ET6414.85
12:08 ET14564.85
12:10 ET1074.85
12:12 ET3104.84
12:14 ET3004.85
12:15 ET11504.83
12:17 ET1004.8299
12:19 ET1004.84
12:21 ET8004.86
12:28 ET27874.9
12:32 ET9004.85
12:46 ET1004.86
12:48 ET1004.87
12:51 ET3994.88
12:53 ET1544.8899
12:55 ET4004.8712
01:02 ET6004.87
01:04 ET1004.86
01:09 ET7004.86
01:15 ET33034.845
01:18 ET5144.845
01:20 ET2004.84
01:24 ET9344.85
01:27 ET1004.85
01:29 ET3004.86
01:33 ET7004.87
01:36 ET57244.89
01:38 ET1004.88
01:40 ET10004.8802
01:42 ET34094.88
01:44 ET5004.86
01:49 ET15004.865
01:51 ET26594.86
01:54 ET20004.86
01:56 ET19084.85
01:58 ET1004.86
02:02 ET59004.845
02:03 ET2004.845
02:09 ET3004.845
02:12 ET6004.845
02:14 ET2004.845
02:16 ET4144.845
02:20 ET14284.85
02:25 ET5004.84
02:27 ET4004.85
02:32 ET4004.85
02:34 ET2004.85
02:38 ET4004.865
02:41 ET3004.86
02:43 ET4004.85
02:45 ET2004.86
02:50 ET4004.86
02:52 ET2004.86
02:54 ET3004.86
02:56 ET45054.85
02:57 ET2024.85
03:01 ET9004.855
03:03 ET3004.86
03:08 ET1134.85
03:12 ET2004.88
03:14 ET7004.86
03:15 ET2004.855
03:17 ET2004.855
03:19 ET6004.855
03:21 ET11284.85
03:24 ET2004.84
03:26 ET13304.845
03:28 ET5824.84
03:30 ET5684.845
03:32 ET8504.845
03:33 ET1004.845
03:35 ET6284.86
03:37 ET14004.8613
03:42 ET1004.865
03:44 ET10384.87
03:46 ET6004.88
03:48 ET10804.87
03:50 ET6004.87
03:51 ET9214.87
03:53 ET38654.89
03:55 ET43894.915
03:57 ET25724.92
04:00 ET641584.92
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKOD
Kodiak Sciences Inc
258.9M
-1.3x
---
United StatesINZY
Inozyme Pharma Inc
258.2M
-2.6x
---
United StatesOMER
Omeros Corp
255.5M
-1.3x
---
United StatesPYXS
Pyxis Oncology Inc
262.6M
-3.5x
---
United StatesCLYM
Climb Bio Inc
254.2M
-1.8x
---
United StatesLXEO
Lexeo Therapeutics Inc
264.5M
-2.8x
---
As of 2024-11-10

Company Information

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Contact Information

Headquarters
1200 PAGE MILL RDPALO ALTO, CA, United States 94304
Phone
650-281-0850
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Victor Perlroth
Chief Financial Officer, Executive Vice President, Secretary
John Borgeson
Lead Independent Director
Robert Profusek
Independent Director
Felix Baker
Independent Director
Charles Bancroft

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$258.9M
Revenue (TTM)
$0.00
Shares Outstanding
52.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.24
EPS
$-3.77
Book Value
$5.06
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.